Clinical Trial Update: Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 feasibility study evaluating the addition of bortezomib to the R-ICE chemotherapy regimen for relapsed or refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Rituximab (rituximab)

Snippet

Sponsor: Singapore General Hospital | Conditions: Diffuse Large B-Cell Lymphoma | Phase 1 | Status: COMPLETED